2020
DOI: 10.1111/jgs.16621
|View full text |Cite
|
Sign up to set email alerts
|

Embedded Pragmatic Trials in Dementia Care: Realizing the Vision of the NIA IMPACT Collaboratory

Abstract: Close to 6 million Americans have Alzheimer's disease (AD) or Alzheimer's disease and related dementia (AD/ADRD). These high-need, high-cost patients are vulnerable to receiving poor quality uncoordinated care, ultimately leading to adverse health outcomes, poor quality of life, and misuse of resources. Improving the care of persons living with dementia (PLWD) and their caregivers is an urgent public health challenge that must be informed by high-quality evidence. Although prior research has elucidated opportu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
84
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 55 publications
(85 citation statements)
references
References 30 publications
(38 reference statements)
0
84
0
1
Order By: Relevance
“…A number of resources have been designed to help include older adults with dementia in clinical trials. The National Institute on Aging Imbedded Pragmatic Alzheimer's Disease (AD) and AD-Related Dementias Clinical Trials (IMPACT) Collaboratory has convened a Design and Statistics Core [55], the goals of which are to support the design and conduct of embedded pragmatic clinical trials in older adults with dementia. The roles of this body include education of scientists and health care providers in trial design, production of literature to address relevant challenges, designing potential interventions to tackle the challenges of multiple comorbidities, and the incorporation of multiple health care systems and stakeholders [56].…”
Section: Competing Comorbiditymentioning
confidence: 99%
“…A number of resources have been designed to help include older adults with dementia in clinical trials. The National Institute on Aging Imbedded Pragmatic Alzheimer's Disease (AD) and AD-Related Dementias Clinical Trials (IMPACT) Collaboratory has convened a Design and Statistics Core [55], the goals of which are to support the design and conduct of embedded pragmatic clinical trials in older adults with dementia. The roles of this body include education of scientists and health care providers in trial design, production of literature to address relevant challenges, designing potential interventions to tackle the challenges of multiple comorbidities, and the incorporation of multiple health care systems and stakeholders [56].…”
Section: Competing Comorbiditymentioning
confidence: 99%
“…The National Institute on Aging (NIA) IMbedded Pragmatic Alzheimer's Disease (AD) and AD-Related Dementias (AD/ADRD) Clinical Trials (IMPACT) Collaboratory is part of a national response intended to transform the delivery of dementia care in health care systems in the United States [3]. The IMPACT Collaboratory has created a nationwide infrastructure funded through a cooperative agreement from the National Institute on Aging in order to promote the conduct of embedded Pragmatic Clinical Trials (ePCTs) that evaluate non-pharmacological approaches to care for people living with dementia (PLWD) and their care partners within healthcare systems.…”
Section: What Is the Nia Impact Collaboratory?mentioning
confidence: 99%
“…Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) are a group of irreversible and progressive brain disorders that manifest across a continuum of cognitive decline, including difficulty in eating, speaking, problem-solving, making decisions, and memory loss that interfere with a person's daily activities [1,2]. Current estimates indicate that 50 million people world-wide live with AD/ADRD [3]. The World Health Organization estimates that the number will triple to more than 150 million people affected globally by 2050 [4].…”
mentioning
confidence: 99%
“…[2][3][4][5][6][7] They are different from explanatory trials mainly in that ePCTs are not conducted in controlled, ideal settings that ascertain outcome data that are outside routine care. 8,9 ePCTs set in LHSs create a unique opportunity for researchers, healthcare providers and organizations, caregivers, and PLWD and their families to work and learn together as potentially effective interventions are studied and stress tested in real-world situations. The nature of ePCTs also provides the kind of experiences and knowledge that, if an intervention is effective, can lead to implementation and sustainability for care practices that are proved effective.…”
Section: Introductionmentioning
confidence: 99%
“…The National Institute on Aging's (NIA's) IMbedded Alzheimer's Disease and AD-Related Dementias Clinical Trials (IMPACT) Collaboratory began in September 2019 and will expand our understanding of how to test AD/ADRD nonpharmacological ePCTs within LHSs and other care settings serving PLWD. 9 The IMPACT Collaboratory is a multisite research network that includes over 60 investigators, more than 30 academic institutions, and 10 working group cores and teams. These cores and teams generate and disseminate emerging knowledge and best practices for conducting ePCTs among PLWD.…”
Section: Introductionmentioning
confidence: 99%